Enjaymo
Enjaymo ingredients
| Active ingredient | Strength |
|---|---|
| Sutimlimab | 50 mg/mL |
What Enjaymo is used for
The FDA lists the approved uses on the official label (below). In the EU, sutimlimab is approved as Enjaymo for:
Enjaymo is indicated for the treatment of haemolytic anaemia in adult patients with cold agglutinin disease (CAD).
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Enjaymo
- Generic name
- Sutimlimab-jome
- Made by
- Recordati Rare Diseases, Inc.
- Forms
- Injection, Solution, Concentrate
- Given
- Intravenous
- Drug class
- Classical Complement Pathway Inhibitor
- FDA approval
- Biologic licence (BLA) BLA761164
- On the US market since
- 2022
Official information
- Enjaymo prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Sutimlimab-jome)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Enjaymo?
Enjaymo (Sutimlimab-jome) is a specialist medicine made by Recordati Rare Diseases, Inc., approved by the US FDA.
What are the ingredients of Enjaymo?
Enjaymo contains Sutimlimab (50 mg/mL).
Is Enjaymo approved in Europe?
The same active substance is approved in the EU as Enjaymo.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA